Cellectis S.A. (CLLS) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CLLS Revenue Growth
Revenue Breakdown (FY 2022)
CLLS's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
CLLS Revenue Analysis (2013–2024)
As of May 8, 2026, Cellectis S.A. (CLLS) generated trailing twelve-month (TTM) revenue of $75.3 million, reflecting explosive growth of +117.1% year-over-year. The most recent quarter (Q3 2025) recorded $35.2 million in revenue, up 110.3% sequentially.
Looking at the longer-term picture, CLLS's 5-year compound annual growth rate (CAGR) stands at +22.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $55.0 million in 2015.
Revenue diversification analysis shows CLLS's business is primarily driven by Therapeutics (100%). With over half of revenue concentrated in Therapeutics, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CRSP (-88.9% YoY), BEAM (+108.0% YoY), and NTLA (+16.9% YoY), CLLS has outperformed the peer group in terms of revenue growth. Compare CLLS vs CRSP →
CLLS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CLLSCurrent | $75M | +117.1% | +22.3% | -143.5% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% |
CLLS Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $41.5M | +5397.5% | $32.3M | 77.9% | $-59,554,000 | -143.5% |
| 2023 | $755K | -96.1% | $-6,664,000 | -882.6% | $-97,302,000 | -12887.7% |
| 2022 | $19.2M | -36.8% | $10.7M | 55.7% | $-89,666,000 | -467.7% |
| 2021 | $30.3M | -40.6% | $28.5M | 93.9% | $-103,481,000 | -341.0% |
| 2020 | $51.1M | +236.1% | $49.1M | 96.2% | $-42,311,000 | -82.9% |
| 2019 | $15.2M | +19.3% | $3.8M | 25.0% | $-123,552,000 | -813.4% |
| 2018 | $12.7M | -49.5% | $10.0M | 78.5% | $-105,091,000 | -825.5% |
| 2017 | $25.2M | -40.9% | $22.6M | 89.6% | $-92,650,000 | -367.8% |
| 2016 | $42.6M | -22.6% | $40.9M | 96.0% | $-63,962,391 | -150.2% |
| 2015 | $55.0M | +109.3% | $52.3M | 95.1% | $-30,529,377 | -55.5% |
See CLLS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLLS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLLS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCLLS — Frequently Asked Questions
Quick answers to the most common questions about buying CLLS stock.
Is CLLS's revenue growth accelerating or slowing?
CLLS revenue is accelerating at +117.1% year-over-year, exceeding the 5-year CAGR of +22.3%. TTM revenue reached $75M. Growth momentum has increased versus prior periods.
What is CLLS's long-term revenue growth rate?
Cellectis S.A.'s 5-year revenue CAGR of +22.3% reflects the sustained expansion pattern. Current YoY growth of +117.1% is above this long-term average.
How is CLLS's revenue distributed by segment?
CLLS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.